Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

被引：0
|
作者：
Gerds, Aaron T. [1 ]
List, Alan F. [2 ]
Giagounidis, Aristoteles [3 ]
Hellstrom-Lindberg, Eva [4 ]
Li, Jack Shiansong [5 ]
Swern, Arlene S. [5 ]
Sugrue, Mary M. [5 ]
Fenaux, Pierre [6 ]
Sekeres, Mikkael A. [7 ]
机构：
[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Clin Sci, Tampa, FL 33612 USA
[3] Marien Hosp, Dusseldorf, Germany
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Celgene Corp, Summit, NJ USA
[6] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
[7] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Blood consult: treating del(5q) myelodysplastic syndromes
    Mukherjee, Sudipto
    Tiu, Ramon V.
    Sekeres, Mikkael A.
    BLOOD, 2012, 119 (02) : 342 - 344
  • [32] Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Guan, Yihong
    Nagata, Yasunobu
    Adema, Vera
    Hasipek, Metis
    Gerds, Aaron T.
    Carraway, Hetty E.
    Advani, Anjali S.
    Przychodzen, Bartlomiej P.
    Santini, Valeria
    Maciejewski, Jaroslaw P.
    Jha, Babal K.
    Nazha, Aziz
    BLOOD, 2018, 132
  • [33] Variability in the extent of del(5q) in myelodysplastic syndromes (MDS)
    Zemanova, Zuzana
    Brezinova, Jana
    Svobodova, Karla
    Lhotska, Halka
    Vesela, Denisa
    Belickova, Monika
    Vesela, Jitka
    Izakova, Silvia
    Sarova, Iveta
    Lizcova, Libuse
    Ransdorfova, Sarka
    Pavlistova, Lenka
    Cermak, Jaroslav
    Stopka, Tomas
    Jonasova, Anna
    Michalova, Kyra
    MOLECULAR CYTOGENETICS, 2019, 12
  • [34] The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
    Melchert, Magda
    Kale, Vishakha
    List, Alan
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 123 - 129
  • [35] Gene expression profiling in patients with myelodysplastic syndromes, including patients with the del(5q)
    Boultwood, J.
    LEUKEMIA RESEARCH, 2009, 33 : S3 - S4
  • [36] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Haferlach, Torsten
    Zhong, Jim
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    MacBeth, Kyle J.
    Almeida, Antonio
    LEUKEMIA, 2021, 35 (03) : 897 - 900
  • [37] Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
    Giagounidis, Aristoteles
    Mufti, Ghulam J.
    Fenaux, Pierre
    Germing, Ulrich
    List, Alan
    MacBeth, Kyle J.
    ANNALS OF HEMATOLOGY, 2014, 93 (01) : 1 - 11
  • [38] Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
    Aristoteles Giagounidis
    Ghulam J. Mufti
    Pierre Fenaux
    Ulrich Germing
    Alan List
    Kyle J. MacBeth
    Annals of Hematology, 2014, 93 : 1 - 11
  • [39] Role of lenalidomide in management of pure red cell aplasia (PRCA) and myelodysplastic syndromes (MDS) with del(5q)
    Cerchione, C.
    Cerciello, G.
    Della Pepa, R.
    Pugliese, N.
    Marano, L.
    Vitagliano, O.
    Luciano, L.
    Alfinito, F.
    Pane, F.
    Risitano, A. M.
    LEUKEMIA RESEARCH, 2013, 37 : S100 - S100
  • [40] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Valeria Santini
    Pierre Fenaux
    Aristoteles Giagounidis
    Uwe Platzbecker
    Alan F. List
    Torsten Haferlach
    Jim Zhong
    Chengqing Wu
    Konstantinos Mavrommatis
    C. L. Beach
    Kyle J. MacBeth
    Antonio Almeida
    Leukemia, 2021, 35 : 897 - 900
12345